A little-known Chinese company made a drug that beat the world’s biggest-selling medicine
China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend isn’t confined to Big Tech: It has been quietly happening in the ...
You thought only DeepSeek routed American titans? Wait, here's a little-known Chinese biotech company whose lung cancer drug could rattle big pharma; here's al…
Chinese biotech company Akeso developed a lung cancer drug Ivonescimab, which outperformed Merck's Keytruda in trials. This ...
When This Professor Got Cancer, He Didn’t Quit. He Taught a Class About It.
Dr. Bryant Lin, who teaches medicine at Stanford University, was given a terminal diagnosis. He wanted his students to ...
BioPharma Dive2d
Summit partners with Pfizer to study bispecific, ADC combinations
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
Cure Today2d
Zongertinib Receives Priority Review For HER2 Mutant NSCLC
Zongertinib, an investigational treatment for HER2-mutant advanced NSCLC, has received FDA priority review, showing positive ...
Medical Xpress9d
Antibody therapy shrinks immunotherapy-resistant lung cancer tumors in mice
By doing so, these drugs enable a patient's own T cells to fight the cancer. ICIs have revolutionized treatment for many ...
Extensive-Stage Small Cell Lung Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
The leading Extensive-Stage Small Cell Lung Cancer Companies such as Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, ...
The Economist10d
It’s not just AI. China’s medicines are surprising the world, too
In recent months China’s progress in artificial intelligence has stunned the world. A quieter yet equally significant shift ...
Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...
Targeted Oncology6h
Study Launches Exploring Peluntamig Combo in DLL3-Expressing Tumors
Dosing has started in a clinical evaluating peluntamig, which targets DLL3 and CD47, combined with chemotherapy in patients ...
Science Daily5d
Lung Cancer News
Drug Improves Effectiveness of Radiation for Lung Cancer That Has Spread to the Brain Oct. 4, 2024 — The University of Cincinnati's Debanjan Bhattacharya is first author of new research ...
New target points to combination therapy for thwarting multidrug resistance in cancer treatment
Multidrug resistance in cancer can be overcome by combining a drug that blocks a key enzyme with another anticancer drug, ...